(+/-)-2-hydroxymethyl-6-<(N-tert-butoxycarbonyl)amino>spiro<3.3>heptane | 170508-15-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (+/-)-2-hydroxymethyl-6-<(N-tert-butoxycarbonyl)amino>spiro<3.3>heptane
• 英文别名: tert-butyl N-[6-(hydroxymethyl)spiro[3.3]heptane-2-yl]carbamate；(racemic)-tert-butyl (6-(hydroxymethyl)spiro[3.3]heptan-2-yl)carbamate；tert-butyl (6-(hydroxymethyl)spiro[3.3]heptan-2-yl)carbamate；tert-butyl N-[6-(hydroxymethyl)spiro[3.3]heptan-2-yl]carbamate
• CAS: 170508-15-3
• 化学式: C₁₃H₂₃NO₃
• 分子量: 241.331
• InChiKey: VHRSRHDORQXSSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+/-)-2-hydroxymethyl-6-<(N-tert-butoxycarbonyl)amino>spiro<3.3>heptane 在 盐酸 、 三乙胺 作用下， 以 甲醇 、 正丁醇 为溶剂， 反应 26.0h， 生成 5-amino-4-chloro-6-((4-hydroxymethyl)spiro<3.3>hept-6-yl)aminopyrimidine
  参考文献：
  名称：

  (.+-.)-N9-(2-(Hydroxymethyl)spiro[3.3]hept-6-yl)adenine. The First Biologically Active Saturated Analog of Adenallene with Axial Dissymmetry

  摘要：

  Synthesis of the title analogue 2 is described. Fecht's acid (3) was esterified with N,N-dimethylformamide dimethyl acetal to give monoester 4 along with diester 5. Compound 4 was transformed to ester amide 6 by the reaction with isobutyl chloroformate and triethylamine followed by ammonolysis. Hoffman rearrangement of 6 effected by lead tetraacetate in tert-butyl alcohol led to the N-tert-butoxycarbonyl ester 7. The latter was reduced with Ca(BH4)(2) to give the protected amino alcohol 8. Removal of the N-tert-butoxycarbonyl group with 2 M HCl in methanol afforded the hydrochloride of amino alcohol 9. Reaction of 9 with 5-amino-4,6-dichloropyrimidine and triethylamine gave the pyrimidine derivative 10 which, in turn, was cyclized to 6-chloropurine 11a. Ammonolysis of the latter intermediate afforded the title analogue 2. The H-1 NMR spectrum of Fecht's acid (3) in CD3COCD3 showed that four methylene protons were magnetically nonequivalent (two quartets) whereas the other four were equivalent, forming a single doublet. Compound 2 inhibited the replication of human cytomegalovirus (IC50 32 mu M) and growth of murine leukemia L1210 cells (IC50 30 mu M). Zone assays showed inhibition of the following tumor cultures at 0.5 mg/disk: murine leukemia P388, mouse tumors PO3, C38, and M17/Adr as well as human tumors MCF-7 and CX-1..

  DOI：

  10.1021/jo00125a011
• 作为产物：
  描述：

  6-(甲氧基羰基)螺[3.3]庚烷-2-羧酸 在 lead(IV) acetate 、 sodium tetrahydroborate 、 氨 、 三乙胺 、 calcium chloride 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.84h， 生成 (+/-)-2-hydroxymethyl-6-<(N-tert-butoxycarbonyl)amino>spiro<3.3>heptane
  参考文献：
  名称：

  (.+-.)-N9-(2-(Hydroxymethyl)spiro[3.3]hept-6-yl)adenine. The First Biologically Active Saturated Analog of Adenallene with Axial Dissymmetry

  摘要：

  Synthesis of the title analogue 2 is described. Fecht's acid (3) was esterified with N,N-dimethylformamide dimethyl acetal to give monoester 4 along with diester 5. Compound 4 was transformed to ester amide 6 by the reaction with isobutyl chloroformate and triethylamine followed by ammonolysis. Hoffman rearrangement of 6 effected by lead tetraacetate in tert-butyl alcohol led to the N-tert-butoxycarbonyl ester 7. The latter was reduced with Ca(BH4)(2) to give the protected amino alcohol 8. Removal of the N-tert-butoxycarbonyl group with 2 M HCl in methanol afforded the hydrochloride of amino alcohol 9. Reaction of 9 with 5-amino-4,6-dichloropyrimidine and triethylamine gave the pyrimidine derivative 10 which, in turn, was cyclized to 6-chloropurine 11a. Ammonolysis of the latter intermediate afforded the title analogue 2. The H-1 NMR spectrum of Fecht's acid (3) in CD3COCD3 showed that four methylene protons were magnetically nonequivalent (two quartets) whereas the other four were equivalent, forming a single doublet. Compound 2 inhibited the replication of human cytomegalovirus (IC50 32 mu M) and growth of murine leukemia L1210 cells (IC50 30 mu M). Zone assays showed inhibition of the following tumor cultures at 0.5 mg/disk: murine leukemia P388, mouse tumors PO3, C38, and M17/Adr as well as human tumors MCF-7 and CX-1..

  DOI：

  10.1021/jo00125a011

文献信息

• BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF
  申请人：Tempest Therapeutics, Inc.

  公开号：US20190315712A1

  公开（公告）日：2019-10-17

  Compounds, compositions and methods are provided for modulating the activity of EP 2 and EP 4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP 2 and EP 4 receptors. In certain embodiments, the compounds are antagonists of both the EP 2 and EP 4 receptors.

  提供了用于调节EP2和EP4受体活性的化合物、组合物和方法，以及用于治疗、预防和改善与EP2和EP4受体活性相关的疾病或疾病症状的一种或多种方法。在某些实施例中，这些化合物是EP2和EP4受体的拮抗剂。
• [EN] ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF<br/>[FR] ANTICORPS ANTI-VISTA HUMAINS ET UTILISATION ASSOCIÉE
  申请人：IMMUNEXT INC

  公开号：WO2021216913A1

  公开（公告）日：2021-10-28

  The invention provides anti-VISTA antibody drug conjugates which may be used for targeted delivery of anti-inflammatory agents such as steroids to immune cells, e.g., myeloid cells. The invention also provides methods of using anti-VISTA antibody drug conjugates in the treatment of inflammatory and/or autoimmune conditions and/or for alleviating the toxicity of anti-inflammatory agents such as steroids.

  本发明提供了抗VISTA抗体药物偶联物，可用于针对免疫细胞（例如，髓系细胞）的靶向递送抗炎剂，例如类固醇。本发明还提供了在治疗炎症和/或自身免疫状况以及/或减轻抗炎剂（如类固醇）的毒性中使用抗VISTA抗体药物偶联物的方法。
• 1,3-BENZODIOXOLE DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3121175A1

  公开（公告）日：2017-01-25

  The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).

  本发明提供了一种具有特定化学结构的化合物或其药理学上可接受的盐，该化合物对 EZH1 和/或 EZH2 的活性具有极佳的抑制作用。本发明提供了一种具有通式（I）所代表的 1，3-苯并二恶茂结构的化合物或其药理学上可接受的盐，或包含该化合物的药物组合物（其中式（I）中的 R1、R2、R3、R4、R5、R6 和 V 均如本说明书中所定义）。
• 1,3-benzodioxole derivative
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US10017500B2

  公开（公告）日：2018-07-10

  The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, or a pharmaceutical composition comprising the compound (wherein R1, R2, R3, R4, R5, R6, and V in the formula (I) are each as defined in the present specification).

  本发明提供了一种具有特定化学结构的化合物或其药理学上可接受的盐，该化合物对 EZH1 和/或 EZH2 的活性具有极佳的抑制作用。本发明提供了一种具有通式（I）所代表的 1，3-苯并二恶茂结构的化合物或其药理学上可接受的盐，或包含该化合物的药物组合物（其中式（I）中的 R1、R2、R3、R4、R5、R6 和 V 均如本说明书中所定义）。
• JP5806438
  申请人：——

  公开号：——

  公开（公告）日：——